Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tenax Therapeutics (NQ: TENX ) 2.770 -0.260 (-8.58%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tenax Therapeutics Tenax Therapeutics Inc. (NASDAQ: TENX) Near the Top of Equities by Percentage Gain on 2/6 February 06, 2024 Via Investor Brand Network InvestorNewsBreaks – Tenax Therapeutics Inc. (NASDAQ: TENX) Announces $15.6M Public Offering February 10, 2023 Via Investor Brand Network Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) February 02, 2023 Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and Via Spotlight Growth Topics Intellectual Property Exposures Intellectual Property Product Safety Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) May 25, 2022 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension May 23, 2022 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules May 18, 2022 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update March 31, 2022 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions March 30, 2022 From Tenax Therapeutics, Inc. Via Business Wire NASDAQ:TENX Shareholder Alert: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc. February 17, 2022 San Diego, CA -- (SBWIRE) -- 02/17/2022 -- Certain directors of Tenax Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties . Via SBWire Investigation for Investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) Shares Announced December 13, 2021 San Diego, CA -- (SBWIRE) -- 12/13/2021 -- An investigation was announced for investors of Tenax Therapeutics, Inc. (NASDAQ:TENX) shares over potential securities laws violations by Tenax Therapeutics,... Via SBWire NASDAQ:TENX Investor Notice: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc. December 01, 2021 San Diego, CA -- (SBWIRE) -- 12/01/2021 -- Certain directors of Tenax Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Via SBWire Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update November 16, 2021 From Tenax Therapeutics, Inc. Via Business Wire NASDAQ:TENX Investor Notice: Investigation over Possible Securities Laws Violations by Tenax Therapeutics, Inc. November 09, 2021 San Diego, CA -- (SBWIRE) -- 11/09/2021 -- Tenax Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH) October 06, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference September 28, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 09, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update August 17, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) August 12, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) August 05, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules July 07, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Set to Join Russell Microcap® Index June 10, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update May 17, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ” April 09, 2021 From Tenax Therapeutics, Inc. Via Business Wire Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders April 07, 2021 From Tenax Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.